Effect of Tepotinib on Pharmacokinetics (PK) of Cytochrome P450 (CYP) 3A Substrate Midazolam
Status:
Completed
Trial end date:
2018-10-30
Target enrollment:
Participant gender:
Summary
The study will investigate the effect of tepotinib on the PK of the CYP3A substrate midazolam
determined from concentrations of midazolam and its main metabolite 1-hydroxymidazolam in
healthy participants.